Modeling variability for biologics strategic planning by Conant, Tamara L. (Tamara Lynn)
MODELING VARIABILITY
FOR
BIOLOGICS STRATEGIC PLANNING
By
Tamara L. Conant
B.S. & B.A. 2001
Seattle University
Submitted to the MIT Sloan School of Management and the Department of Electrical
in Partial Fulfillment of the Requirements for the Degrees of
Master of Business Administration
AND
Master of Science in Electrical Engineering
In conjunction with the Leaders for Manufacturing Program at the
Massachusetts Institute of Technology
June 2009
C 2009 Massachusetts Institute of Technology. All rights reserved
Signature of Author
May 8, 2009
MIT Sloan School of Management and Department of Electrical Engineering
-7
Certified by.
Clrles Cooney, Thesis Supervisor
Rq T. Haslam Professor of Chemical Engineering
Ernst Berndt, Thesis Supervisor
Louis E. Seley Professor in Applied Economics
Certified by
MASSACHUSETTS INSTITUTE
OF TECHNOLOGY
AUG 0 7 2009
LIBRARIES
Engineering
ARCHIVES
Accepted by
Professor Terry P. Orlando
Chair, Department of Electrical Engineering Committee on Graduate Students
Accepted by IDebbie Berechman
Executive Director of MBA Program, MIT Sloan School of Management
This page has been intentionall, left blank.
Modeling Variability for Biologics Strategic Planning
by
Tamara L. Conant
Submitted to the MIT Sloan School of Management and the Department of Electrical Engineering
on May 8, 2009 in Partial Fulfillment of the
Requirements for the Degrees of Master of Business Administration and
Master of Science in Electrical Engineering
ABSTRACT
Making strategic decisions about resource capabilities in the uncertain business of drug development
is a challenging task. Novartis, a Swiss pharmaceutical company, is expanding from its success in
small molecule therapeutics into the attractive area of biologic therapeutics, both monoclonal
antibody and microbial forms. While Novartis has experience developing these types of
therapeutics, they have not fully-developed the quantity that the Research group expects to source
the pipeline with in the next few years. Therefore the Development group needs to grow.
Determining the right number and type of scientists and technicians to hire is difficult due to the
variability in the portfolio. The long development timelines, low and variable success rates impact
how projects progress through the pipeline. A Monte Carlo simulation model forecasts variability
and displays a numerical range of projects and headcount requirements expected for several years.
This data is essential for project managers, function heads, and operations leaders to develop the
five-year strategic plan for biologic development. This model quantifies the uncertainty of input
variables to deliver a calculated risk of output variables, which provides useful and important
information for making strategic business decisions.
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GLOSSARY
Biosimilar: a generic or follow-on biologic, either mAb or microbial
EMEA: European Medicines Evaluation Agency, the European regulatory agency that approves
pharmaceuticals and medical devices for commercial sale and use
FDA: Food and Drug Administration, the United States federal regulatory agency that approves
pharmaceuticals and medical devices for commercial sale and use
Microbial: protein-based molecules expressed in a simpler E. Coli or yeast cell, a type of biologic
therapeutic
Monoclonal antibody (mAb): complex protein-based molecules produced by B-lymphocytes that
bind to and help eliminate foreign and infectious agents in the body (Reichert, 2005), a type of
biologic therapeutic
Phase I/POC/IIa: first clinical trials to explore the safety and tolerability of patients to a drug,
small patient population, shorter in length (Rang, 2006)
Phase lib: clinical trial to confirm dose selection, larger patient population, longer time (Rang,
2006)
Phase III: clinical trial to confirm efficacy and safety to support registration, large patient
population, long time (Rang, 2006)
Probability of success: the chance that a drug candidate has to progress from one development
stage to another, based on data from clinical trials
Submission: a development phase that accounts for the time between when data is submitted to the
FDA and when a drug is officially approved
INTRODUCTION
Pharmaceutical Overview
The pharmaceutical industry exists to discover, develop, produce, and market therapeutic drugs
to alleviate disease states and symptoms. The industry relies heavily on scientific research to
discover molecules that target specific disease pathways. This research creates the intellectual
property, in the form of patents, which create value for the companies who eventually sell those
drugs to patients. While blockbuster drugs can bring in billions of dollars in revenue,
pharmaceutical discovery and development is a lengthy, risky and costly process. Across the
industry a drug typically takes over ten years and costs over $1 billion to bring to market. This
includes the fact that only twenty percent of drugs that start down the clinical development
pipeline actually make it to the market. (DiMasi, 2007)
Organizationally, most pharmaceutical companies are organized into four groups; Research,
Development, Operations, and Marketing. Research identifies target molecules that act to alleviate
disease symptoms or address causes. Then Development determines how to scale up the process
of creating the molecules into a robust manufacturing process. This occurs in conjunction with a
series of clinical trials, which examine and evaluate the safety and efficacy of the drug in a selective
patient population. The form and amount of material required for these trials varies by disease
specifics and clinical trial designs. The purpose of clinical trials is to generate sufficient data to
present to the regulatory agencies, like the FDA and EMEA, in order for them to approve the drug
for commercial use. Operations is responsible for the full-scale manufacturing plants and
commercial campaigns. The hand-off between Development and Operations usually occurs before
Phase III clinical material is produced so that validation runs can take place in the same facility
before commercial launch. Marketing ensures that drugs reach the appropriate patients once they
are approved for commercial use.
The pharmaceutical industry started over a century ago and has progressed from mixing
chemical compounds to growing biological proteins. Today, there are two main classes of
therapeutic drugs. Small-molecule therapeutics are composed of chemical compounds formed
through relatively simple manufacturing processes. Biologic therapeutics, or biologics, are
composed of proteins and are manufactured inside living cells in a more complex process.
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Biologics Overview
Biologics arose from scientific breakthroughs in the 1970's and grew through the emergence of
biotechnology (biotech) firms. Biologics have grown in the past few decades due to their high
research and development productivity in areas of unmet medical need. Most industry consultants
predict that pharmaceutical sales will grow more quickly in biologics than small molecules over the
next ten years. (Drews, 2003) That may be due to the saturation of small molecule therapeutics and
their follow-on generics that increase competition, erode sales, and reduce margins. Historically
biologics have not faced as much competition, although that is changing as more companies focus
on biotechnology. The EMEA recently approved the use of follow-on biologics or biosimilars, but
no company has successfully brought a biosimilar to market due to the highly-complex
manufacturing processes and necessity of conducting some clinical trials. This market trend may
also be driven by the reluctance of the regulatory agencies to approve new drugs that do not address
an unmet medical need or show a significant improvement over patient outcomes than drugs on the
market.
The higher research productivity and easier competitive landscape associated with biologics has
attracted the attention of the traditionally small molecule, large pharmaceutical firms. (Drews, 2003)
Therefore more pharmaceutical companies are either forming partnerships or alliances with smaller
biotechnology firms or creating new biologics divisions within Research, Development, Operations,
and Marketing. Strategically, the goal is to expand and diversify portfolio pipelines and increase
research and development productivity.
Organizational Assessment
Novartis AG (NYSE: NVS) is a diversified healthcare company consisting of four divisions:
Pharmaceuticals, Vaccines and Diagnostics, Sandoz (Generics), and Consumer Health. Novartis
was legally formed in 1996 with a merger between Ciba-Geigy and Sandoz. Novartis Pharma AG
(the pharmaceuticals division) generates the largest revenue, $24 billion in 2007, and contains the
most resources, employing over 54,000 associates in 2007. This division is headquartered in Basel,
Switzerland, but it occupies multiple sites across the globe. Currently their portfolio contains over
45 key marketed products, which diversifies their revenue into several disease areas and countries. A
significant portion of annual revenue is reinvested in research and development. For Novartis, this
included $5.1 billion in 2007. Novartis Pharma AG has been very successful in bringing new
products to market. It has received 17 new pharmaceutical product approvals in the US since 2000,
which is the most of any pharmaceutical company. (Novartis AG Web site) However, like other
pharmaceutical companies, Novartis Pharma AG also is expanding into biologics. This is consistent
with the corporate diversified strategy that is a huge advantage to shareholders in terms of mitigating
the riskiness of drug development.
Novartis Biologics (NBx) is a newly-reorganized unit within the Development division of
Novartis Pharma AG. They are responsible for delivering scientific expertise as well as
comprehensive oversight for biologic projects from protein or antibody design up through Phase II
of clinical development. They also provide support for biologic projects during both early stages of
research and later stages of development and commercial production. An important group within
NBx is Process Sciences & Production (PSP), which is responsible for process development and
production across 4 groups: Process Sciences, Clinical Manufacturing, Quality Control, and Project
Management. With expertise in cell and molecular biology, fermentation, protein purification,
protein characterization, bioanalytics, and bioreactor engineering, they advance laboratory-created
molecules into pilot plant material for clinical trial use and then into full-scale manufacturing plant
batches suitable for commercial sale. Not only is the process and analytical development technically
difficult for the unique molecules, but also quality and stability of the manufacturing process must
be rigorously tested. There is a comparable biologics-focused unit within the Research and
Operations division of Novartis. In addition, Sandoz operates several biologics facilities that are
designated for future use in developing and producing biosimilars.
Due to the projected pipeline growth and the new strategic emphasis on biologics, NBx has
been asked to increase its resources to accommodate many new projects. While management is
determined not to delay clinical trials by placing development activities on the critical path, they also
do not want to increase headcount to a point where capacity is underutilized due to pipeline
uncertainties. The organization needs to remain flexible to portfolio realizations as projects progress
to later development stages. This is very difficult to predict due to timeline delays and probabilities
of success. Also if the organization grows too quickly, space, training, and cohesion among groups
become issues that require more attention.
While Novartis' size brings resource and investment strength, it also results in multiple
approval processes. Although there are matrixed teams around projects, direct communication
between divisions is weak, especially in terms of resource planning in Development and Operations.
The management of each division creates its own strategic plans which are presented to higher
management teams, in this case meeting and often conflicting at the Pharmaceuticals CEO level or
higher. Ideally Novartis should share resources across divisions to quickly adapt to market trends
and efficiently utilize headcount and equipment capacity. There is also a push to develop third party
contracts that create the option to outsource some projects. While this requires extra internal
headcount to manage the collaborations and usually costs more and takes longer than developing the
project internally, it increases the organization's flexibility in deploying its internal human resources.
Summary
Novartis Pharma AG is a very successful and innovative global pharmaceutical company that is
fortunate to be part of a diversified healthcare company which provides adequate investment and
resources for internal growth. Following industry trends and expanding its pipeline portfolio,
Novartis made a strategic decision to invest in internal capabilities for biologic development. The
challenge is to balance internal growth with the flexibility of third party contracts. Determining the
right amount and timing of internal growth is also challenging for the Biologics management team,
especially with the high uncertainty of the pipeline portfolio.
BIOLOGIC DEVELOPMENT STRATEGY
Risk and Variability in Biologic Development
Biologic discovery and development is a risky business model. Once a potential target
molecule is found, a company must spend millions of dollars to test it in clinical trials which take
eight years on average and typically have about a twenty percent success rate of reaching regulatory
approval. (DiMasi, 2007) In addition, every molecule is different; although there are standard cell
lines and process development steps, there is a high level of variability around developing good
manufacturing processes supporting commercial production. In Science Business, Gary Pisano
describes the uncertainty involved in biologic development as falling into two categories. Primary
uncertainty deals with "unknown unknowns." This correlates to the uncertainty of the science
behind identifying target molecules and learning how they interact with various disease mechanisms,
which confronts academic and professional researchers. Even with years of research experience, it is
hard to predict how a target molecule will act in human patients. Secondary uncertainty deals with
the "known unknowns" that can be described by probability distributions. (Pisano, Science Business:
The Promise, the Realiy, and the Future of Biotech, 2006) This correlates to the time per phase and
probabilities of success per phase that development organizations try to plan around. Historical data
collected in studies like the 2007 Cost ofBiopharmaceutical R&D study by the Tufts Center for the
Study of Drug Development gives industry averages in timelines and probabilities of success.
(DiMasi, 2007) This data can be used to construct probability distributions to forecast pipeline
portfolio success.
Project Statement
Novartis Research predicts a drastic increase in its biologic pipeline over the next ten years, so
Development needs to increase its internal resources to meet these demands. However, the
resources required for the development of a biologic project are difficult to estimate due to the
variability in the time and probability of success of each development phase. Aggregated across a
portfolio, strategic resource planning becomes even more difficult. Additionally, Novartis is feeling
pressure from the market drug pricing in hopes of curtailing the increasing cost of health care,
especially in the United States. This translates into internal corporate goals to reduce development
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costs and increase productivity. Therefore internal resource growth must be carefully forecasted to
maintain organizational capacity and flexibility.
Project Objectives
The goal here is to develop a model to forecast for resource needs across a portfolio of biologic
development projects. By defining input variables with probability distributions, the model predicts
a frequency distribution for headcount requirements with an associated probability of occurrence.
The model should be easy to update and delivers forecasts within a working day. The model should
be usable by Development by the end of the project timeline.
Approach
First, I seek to understand the organization and context of the project objectives. This involves
a literature review of the pharmaceutical and biotech industries, resource planning, and modeling.
This also includes interviews with various leaders and associates within Novartis Biologics and other
areas of the company, such as Portfolio Management and Information Systems. Resource planners
at other companies are questioned to develop industry benchmarks. Next, internal data are collected
on required capacities for development activities to build data templates for different types of
biologic projects. Then a draft model addresses the requested attributes. The draft is tested with
example scenarios and improvements are implemented. The final model runs the desired portfolio
scenario and shows forecasts to create a strategic resource plan. Finally, this thesis documents the
model assumptions, shows a scenario analysis, makes strategic recommendations from the model
output, and provides instructions for users to operate the model.
Timeline
The introduction to the industry and company through interviews and literature review took
two months to complete. The research on modeling techniques and data collection took one month
initially, but was revised later. The draft model took two months to build and improve. The final
model was ready in the fifth month of the project. The sixth month was spent presenting the model
and implementing feedback as well as documenting the model and its assumptions in this thesis
document. The model was in use by Development and Operations in the sixth month, which is
when the project was completed.
Summary
While biologic development is risky, novel therapeutics are approved to meet unmet medical
needs and create corporate profits which allow for further investment in research and development.
Therefore pharmaceutical and biotech leaders must find tools to manage the uncertainty inherent in
their business models. Specifically, Development needs a tool to forecast internal resource growth
requirements that accounts for the uncertainty in the pipeline portfolio. The management team
wants a model that easily shows headcount ranges based on pipeline projections, timeline variability,
and probabilities of success. Through a literature review, data collection, and model drafts, a final
model provides improved data for strategic resource planning.
LITERATURE REVIEW
Biologic Drug Development
The literature review of biologic drug development focuses on different strategies in timing and
flow of development activities. This outlines the necessary development activities and areas for
flexibility. Gary Pisano describes the key organizational challenges that confront process
development groups in The Development Factory. Basically, process development exists to transform a
complex, inefficient, and potentially unsafe process from the laboratory to a practical, efficient,
robust, and safe process suitable for a commercial manufacturing plant. (Pisano, The Development
Factogy: Unlocking the Potential of Process Innovation, 1997) In biologic development this usually takes
three steps, a pilot plant campaign, a medium-scale manufacturing campaign and a full-scale
validation campaign. Each campaign consists of three to five batches of material. While the
campaigns test process design and improvements, they are also critical to provide material to
conduct clinical trials and quality control testing. Organizationally, companies split pilot plant and
manufacturing plant operations and management. It is usually less expensive and faster to run a
campaign in a pilot plant; however market demand usually requires a larger amount of material and
therefore a larger-scale plant for commercial production. (Heinzle, 2006) Since regulatory agencies
also approve manufacturing processes and specific plant operations, at least one validation campaign
must occur prior to the launch campaign.
The goal of development organizations and project managers is to reduce the development and
production time and costs. Although clinical trials generally determine the critical path in products
being approved and launched, a biotech's competitive advantage derives from its ability to rapidly
and efficiently develop processes. "The goal here is to create an overall optimal process for the
production of the desired product." (Heinzle, 2006) Plus, the faster a product is launched and the
less it costs to launch, the higher sales and profit margins will be due to increased time on the
market with patent protection. With these goals in mind, the organizational structure and interfaces
between Development and Operations are the keys to smooth development transitions. It is clear
that tech transfer, when processes are scaled up and transferred between facilities, is a key
competency that affects timelines and costs. Efficient tech transfers require practice and good
communication between development groups, a task that larger organizations trying to emphasize
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new areas find difficult. (Pisano, The Development Factoy: Unlocking the Potential of Process Innovation,
1997)
Biologic development has not yet been standardized like other pharmaceutical and industrial
processes. There is an industry push to deploy the same cell lines and create development
platforms. This strategy can streamline the development process by allowing most projects to use
the same techniques in the same order. However, it will be difficult to standardize biological
processes in the same manner as Toyota has with auto manufacturing or Intel has with
semiconductor manufacturing. Another area for improvement is the yield from the manufacturing
process. The yields have increased significantly at Novartis over the past five years. Based on the
new yields, the future strategy is to run more campaigns in the pilot plants since the output is similar
to larger, older plants, but less expensive to produce.
Another area in which pipeline portfolio uncertainty affects key decisions is in infrastructure
investments. The high cost and long timelines of building a new, FDA-approved manufacturing
facility make investment decisions risky. Companies cannot afford to delay development due to lack
of capacity in pilot and manufacturing plants, but they also cannot afford to let plants and operators
sit idle if the pipeline portfolio fizzles out in early stages. Novartis has an advantage in this respect
because it can share capacity with Sandoz, which is developing biosimilars in identical plants.
Another popular option is outsourcing. Third-party contracts provide the option to pay another
company to perform some or all development steps. Although this typically requires more time and
internal resources to manage the contracts, the cost of building an idle plant can be higher and take
longer to respond to portfolio changes. Novartis has taken advantage of this flexibility as it tests the
stability of its newer pipeline prospects.
Simulation Modeling
The literature review of simulation modeling looks at how to model risk and uncertainty. It is
important to keep in mind the organizational goals and limitations and well as user background.
Novartis has a robust project management software program to track the progress and costs of
specific projects. Development project managers apply a standard template and adjust the time,
resources, and costs according to the technical differences with each project. The actual time,
resources, and costs are recorded as the project progresses through the development stages. The
timelines are adjusted if the project is delayed. While this software is useful in tracking projects and
predicting headcount and budget needs for the upcoming year, it does not determine resource needs
beyond the next year or analyze how resource needs of different projects in the portfolio overlap.
Prior to this project and model, the Development approach for strategic planning was to
manually cut and paste a project template over multiple years for the forecasted number of projects
from Research. Then as the projects progressed through the development stages, the template was
changed to account for each projects' specific timeline. This was a very time consuming process.
This method delivered a single number for a headcount forecast output, which gave no information
about probability of occurrence or risk.
Monte Carlo simulation models allow for a random sampling as input variables; therefore they
account for variability within the input factors as defined by probability distributions and show a
probability of occurrence for output factors. This allows the user to evaluate the risk associated with
strategic planning. Crystal Ball is a commercial Monte Carlo simulation software program. I chose
Crystal Ball because it interfaces with Microsoft Excel spreadsheets and is easy to use. In addition,
Novartis already owned a version of the software and I thought I could easily adapt it to a
Development strategic planning model.
The basic principle of a simulation model is "putting into a single framework the best available
information and knowledge about the strategy or structure of the system being studied, the
outcomes of interest, and the risks, rates and probabilities affecting each action." (Stahl, 2008) I
chose this approach because more industry historical data was available than Novartis historical data.
I also want to capture the portfolio uncertainty, but avoid accounting for project specific data. The
model runs a portfolio simulation in a few hours by changing one sheet of input variables, rather
than manually adjusting an assortment of projects.
Benchmarking
Strategically, Novartis is motivated to compete with two successful biotech firms, Amgen and
Genentech. Novartis partnered with Genentech on two successful biologics in the past few years.
Although Genentech completed the process development steps for both of these drugs and helped
design the scaled-up manufacturing processes, Novartis learned and profited immensely from these
projects. Novartis is investing in building biologic capabilities in Research and Development and
adapting organizationally and technically to augment its knowledge gains. Genentech and Amgen
have well defined process development steps and cell lines. Novartis recently acquired a new, robust
cell line and is rapidly improving the speed and quality of process development technical capabilities.
One approach is to match the resources that these biologics organizations devote to the first stage
of process development. Committing more resources up front to perform process development
activities at risk, prior to passing the first clinical trial, may require a larger workforce, but the
tradeoff is less work in later development stages and a faster track through scale up manufacturing
activities.
I spoke with employees at Amgen about portfolio modeling techniques for resource planning in
development stages. Similar to Novartis, they use an Excel model that is linked to a Microsoft
Access database of project information. They manually run portfolio scenarios through an Access
macro, but it does not provide all the desired outputs. They are interested in a better way to model
the risk and uncertainty of the development portfolio.
Organizational Interviews
One of the biggest challenges Novartis faces in growing its biologic capabilities is efficiently
constructing this new organization. I spoke with 15 leaders in Development, Operations and
Portfolio Management to understand how the organization is dealing with its changing structure.
The project managers are responsible for the technical development activities and material
production for clinical trials. They work in matrixed teams to coordinate the timeline of
development activities with the clinical trial schedule. While they plan the project schedule years in
advance, they encounter time delays that jeopardize the material supply for clinical trials. Some of
the time delays are due to the variability of the project's success in process and analytical
development activities. Others are due to the yield from the pilot plant campaigns. Both of these
issues occur because new methods and technological advances are being implemented and
standardized. As more projects progress down the development path, the organizational efficiencies
will improve and the project managers will have an easier time coordinating development activities.
The functional group leaders in Development have a different view of the organizational
changes. They are already dealing with the increasing number of projects and pressure to perform
more activities with the same number of people. As they hire more scientists to accommodate the
increasing growth, they become cramped for both laboratory and pilot plant capacities. Therefore
the organization spreads out into new spaces and breaks off into more segmented functional groups.
This leads to communication challenges and more tech transfers, actions that tend to delay a project.
These group leaders have resource planning models to plan the number and type of scientists in
each of their groups. Models account for the uncertainty around when projects start and how far
they advance in the development pipeline. However they are manually intensive and segmented by
group, so not easy to duplicate for a larger, more diverse group.
The business groups have a different view of biologics and portfolio modeling. I spoke with
the Development and Corporate finance teams as well as the Development portfolio management
teams. The finance teams are responsible for forecasting budgets for the next year. They work
closely with the project managers and functional group leaders to predict their project and group
needs for the upcoming year. While they are heavily involved in strategic planning, they do not use a
specific model to forecast budget and investment needs. They would like a model to gain a better
idea of the probabilities associated with their budget projections. They run high and low risk
variations of the budget, but these are manually intensive. The portfolio management teams use
modeling extensively. Most of the models I saw were Excel based or variations of financial
modeling software. They are more concerned with portfolio net present value (NPV) projections
and how time and probabilities of success affect NPVs. They revise forecasts as projects progress
down the development pipeline. The Development portfolio management group is organized by
disease area, so they do not separate biologics from small molecule projects. They have not seen a
biologic project progress entirely through the Novartis pipeline, so they have limited historical data
for the models. They use Novartis small molecule historical data and adjust it slightly with biotech
industry historical data. As Novartis launches its own biologics and develops data about company
specific timelines and probabilities of success, that data should be used to forecast biologic NPVs. I
believe as the percentage of biologics in Novartis' portfolio grows a difference in risk and
uncertainty will appear. I did not speak with any marketing groups, but it would be interesting to see
how they view the difference between biologics and small molecule products.
Summary
Overall, the literature review of drug development resource modeling reveals the need for a
simulation model to quantify risk and variability. Such a model leads to better strategic planning
decisions in an uncertain business and scientific environment. While there are multiple options, a
Monte Carlo simulation model fits the desired business and scientific inputs and outputs. Crystal
Ball is a user-friendly software program that allows for Monte Carlo simulations and calculations in
an Excel spreadsheet format. Although there is no industry standard model, learning how biotech
companies manage the uncertainty of biologic development is useful and important in this
competitive space. Organizational structure impacts resource planning strategies and decisions.
Novartis has changed the Development organizational structure as they adjust internal capabilities
with external comparisons. As these changes settle out, groups solidify, and processes become
standardized, organizational efficiency and productivity will improve even more.
RESOURCE PLANNING MODEL
Model Statement
To aid in strategic planning, a simulation model determines headcount requirements by year.
The model also attempts to express the variability in the requirements by providing a forecast range
and associated probability of occurrence.
Approach
This is possible with the use of Crystal Ball, a Monte Carlo simulation software. The model is
described in this chapter and is included in Appendix A. An example scenario analysis and
associated strategic recommendations are also included. A user guide is written in Appendix B.
Data in this thesis is altered for demonstrative purposes and does not reflect actual Novartis data.
Data Collection
The first task is to gather data on project activities and associated working days in order to
create a template for the headcount required per project. Templates were created to account for
different models of monoclonal antibody (mAb), microbial, and biosimilar development. The
templates include Development and Operations activities in the following groups: Process
Development, Analytical Development, Drug Substance (DS) Production, Drug Product (DP)
Production, Quality Control, Formulation and Project Management. The activities are further
broken down by development stage. Each activity is listed under the corresponding stage and group
along with the total number of associated working days. These working days are then allocated to a
cell(s) corresponding to the specific quarter(s) along the development timeline in which they occur.
The result is a matrix of activities by quarter that can be summed to find headcount per quarter and
then simplified into a matrix of headcount by phase by group. The headcount is calculated by
multiplying the number of working days by the ratio [1 FTE = 200 working days] and the ratio [1
headcount = 80% project work per FTE]. This percentage of project work per FTE is variable, but
is assumed to be 80%. The simplified matrices for three of the templates are shown in Figure 1,
Figure 2, and Figure 3. These form the main data input for the model.
Choose one:
Process Analytical Production Production
nluelnnmen Development DS DP
Quality
Control
Project
Formulation Management
Project Headcount
Preclinical 14 5.0 5.0 0.0 0.0 2.0. 1.0 1.0
PhlPoC Phlla 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Phllb 14 5.0 5.0 0.0 0.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2..0 2.0 1.0 1.0
Phll 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Submission 3 0.0 0.0 0.0 0.0 2.0 0.0 1.0
Total Headcountiproject 136 35 35 25 10 16 7 8
Figure 1: mAb Headcount Template Matrix
Choose one:
Process Analtical :Production Production Quality Project
Manual assumptions Development Development DS DP Control Formulation Management
Project Headcount
Preclinical 14 5.0 5.0 0.0 0.0 2.0 1.0 1.0
Phl&PoCPhlla 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2 . 0 1.0 1.0
Phllb 14 5.0 5.0 0.0 0.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
PhIll 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Submission 3 0.0 0.0 0.0 0.0 2.0 0.0 1.0
Total Headcountiproject 136 35 35 25 10 16 7 8
Figure 2: microbial Headcount Template Matrix
Choose one:
Process Analgtical Production Production Quality Project
Manual assumptions Development Development DS DP Control Formulation Management
Project Headcount
Start 14 5.0 5.0 0.0 0.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Preclinical 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Phi 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
PhIll 21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
21 5.0 5.0 5.0 2.0 2.0 1.0 1.0
Submission 11 0.0 0.0 5.0 2.0 2.0 1.0 1.0
4 0.0 0.0 0.0 0.0 2.0 1.0 1.0
Total Headcountproject 134 30 30 30 12 16 8 8
Figure 3: biosimilar Headcount Template Matrix
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The standard project timeline is shown at the top of each template. This includes the
Milestones, Tox Studies, Clinical Studies and Material Campaigns distributed along the eight year
timeline. The phases are listed above the years and are defined by the following times:
mAb and microbial timeline biosimilar timeline
Preclinical Year 1 Start Year 1 and 2
Phl\PoC\PhlIa Year 2 and 3 Preclinical Year 3
PhIIb Year 4 and 5 PhI Year 4
PhIII Year 6 and 7 PhIII Year 5 and 6
Submission Year 8 Submission Year 7 and 8
It is also possible to manually select assumptions for the headcount by phase by group matrix.
Other desired headcount numbers, such as data obtained from benchmarking with other companies,
can be entered into a headcount matrix in the data templates. There is a drop-down list included in
the model to choose either "Novartis data templates" or "Manual assumptions" as the source of the
headcount matrix. This feature maintains the link between the model and the data templates while
allowing for easy changes to the headcount assumptions.
Model Description
The goal is to develop a model to forecast resource needs across a portfolio of biologic
development projects. By defining input variables with probability, distributions, the model uses
Crystal Ball to predict a range of headcount requirements with an associated probability of
occurrence.
The Input Variables tab, as shown in Figure 4, uses both manual (yellow-highlighted cells) and
Crystal Ball (green-highlighted cells) variables. There are two types of manual variables and three
types of Crystal Ball variables.
Year T et
2
3
4
8
Time in Phase (pears)
mAb and microbial elkeliest
Preolinical
PhlhPoCPhlla
Phllb
Phll
Submission
Total 8
Probabilit, of Success
mAb and microbial mean
Preclinical - Phi
Phl - PhIlb
Philb -Phill
Phlll - Approval
X at risk
Phllb Dev. Activities Performed at Risk
r d ^ e) ^ r i k i
mM - 2 step microbial
biosimilar mean
Start- Phi
Phi- Approval
mAb - 3 step mAb - 2 step
25x 0%O
25%, 25%
microbial
25X
25%
I--nlll D.JeV.I.IPv> I-t lrVIIes IPe uorm rtl) s/ . .... ....
Figure 4: Model Input Variables Tab
The first manual input is the current number of projects per phase, which can be obtained from
the current project pipeline. The input cells are shown in Figure 5.
Current Projects
microbial
mAb and microbial biosimilar &
expected timeline year phases mAb - 3 step mAb - 2 step microbial vaccine biosimilar phases mAb biosimila
1 Preclinical 5 0 0 0 Start 5
2 PhliPoC;Phlla 5 0 1 1 2
3 0 0 0 1 Preclinical 0
4 Phllb 3 0 3 1 Phi 0
5 0 0 0 0 Phll 3
6 Phll 2 0 2 2 0
7 0 0 1 0 Submission 0
8 Submission 0 0 0 0 0
Figure 5: Manual Input - Current Number of Projects per Phase
The second manual input is the percentage of projects to be performed at risk (development
work completed prior to outcome of phase transition data or decision). For example, the Phase IIb
activities performed at risk occur prior to the results of the Phase I\PoC\PhIIa clinical trial. The
input cells are shown in Figure 6.
x at risk
Phllb Dev. Activities Performed at Risk
Phill Dev. Activities Performed at Risk
mAb - 3 step mAb - 2 step microbial
25% 0 25
25x 25x 25x
Figure 6: Manual Input - Percentage of Projects Performed At Risk
biosimilar &
vaccine
mAh
biosunila
biosimilar
Start
Preclinical
Phi
Phll
Submission
Total
std dev
000 -g 9 rolc!I
The first type of Crystal Ball input variable is the number of incoming projects, which are
defined by discrete, custom distributions, as shown in Figure 7. The likeliest target from Research is
given the highest probability of occurrence. A minimum and maximum are also included with lower
probabilities. These variables differentiate between mAb, microbial, and biosimilar projects, include
in-licensed projects but exclude outsourced projects. There are separate variables for eight years.
The second type of Crystal Ball input variable is more of a stated assumption than a user-
changed input. The time per development phase is defined by a BetaPERT distribution with
historical minimum and maximum times per phase. The BetaPERT distribution is commonly used
in project management models to estimate task and project duration. The likeliest time per phase is
assumed to match the project timeline used in the headcount templates. The distributions for each
of the five phases in mAb and microbial development are shown in Figure 8 through Figure 12.
Edit View Paamrneters Preferences Help
Name: timePredinical
BetaPERT Distribn--
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0.80 1.00 1.20 1.40 1.60 1.80
nimum Likeliest I t.00 Maximum 2.00
Figure 8: Crystal Ball Input -Tie in Preclinical PhaseFigure 8: Crystal Ball Input - Time in Preelinical Phase
Name: ]timePhI\PoC\PhIIa
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Figure 10: Crystal Ball Input - Time in Phase IIb
Edit View Parameters Preferences Help
Name: timePhill
BetaPERT Distribulion
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Figure 11: Crystal Ball Input- Time in Phase III
3.00
Mnimum j
0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40
3 -Infinity 1, ( Infinity 1,
MininWM Ji ULkdlest 1b j Maoijn 2.50
OK Cancel -Eter Galleiy Correate... Help
Figure 12: Crystal Ball Input - Time in Submission Phase
The third Crystal Ball input is also more like a stated assumption. The probability of success
for each phase is defined by a normal distribution with a standard deviation. The normal
distribution was chosen because the historical average is a good indication of the outcome of a large
group of projects, like the Development portfolio. This follows the central limit theorem, which
states conditions under which the sum of a sufficiently large number of independent random
variables, each with finite mean and variance, will be approximately normally distributed. (Rice,
1995) The four phase transition probabilities of success in mAb and microbial development are
shown in Figure 13 to Figure 16. The mean originates from the Tufts Center for the Study of Drug
Development 2007 study on The Cost ofBiopharmaceutical R&D. (DiMasi, 2007)
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Figure 13: Crystal Ball Input - Probability of Success Preclinical Phase to Phase I
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Figure 14: Crystal Ball Input - Probability of Success Phase I to Phase IIb
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Figure 15: Crystal Ball Input - Probability of Success Phase Ilb to Phase III
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Figure 16: Crystal Ball Input - Probability of Success Phase III to Submission
i..Name: r  Phill
There is an output tab for each type of project: mAb, microbial, and biosimilar. The number of
projects and headcount within the tabs are calculated using the target number or mean for number
of incoming projects, time in phase, and probability of success for a phase. The Crystal Ball output
forecasts appear in separate windows.
The model calculates headcount requirements per year with this formula:
Headcount per year = Number of projects * Probability of success that a project progresses * Time
factor * Headcount for current phase * At risk factor
The project time factor tracks if a project uses the full headcount allotted in the year designated
for the normal corresponding phase. If the project progresses according to the likeliest timeline, the
project time factor equals 1.0. However if the project gets delayed, the headcount for the delayed
phase(s) are stretched out over the number of years that it takes to complete those phases. The
projects transition to the subsequent phase the year after completing the current phase. The project
time factor matrix is shown in Figure 17.
project time factor
Preclinical 1.0 0.0
Phi\PoC\Phila 1.0 0.0 0.0
1.0 0.0 0.0
Phllb 1.0 0.0 0.0 0.0
1.0 0.0 0.0 0.0
PhIll 1.0 0.0 0.0 0.0 0.0
1.0 00 0.0  . 0.0
Approval 1.0 0.0 0.0 0.0 0.0 0.0
Figure 17: Model Calculation - Project Time Factor
The model uses a nested if statement to calculate each cell in the project time factor matrix. For
example, the third year of the Approval phase correlates to the following if statement:
=IF(time_Preclinical>1, IF(time_PhI\PoC\PhIIa>2, IF(timePhIIb>2, 0,
IF(time_PhII>2, 0, IF(time_Sub>1, (1/timeSub),1))), IF(timePhIIb>2,
IF(time_PhII>2, 0, IF(timeSub>1, (1/timeSub),1)), IF(timePhIII>2,
IF(timeSub>1, (1/time_Sub),1), IF(time_Sub>1, 1-(1/time_Sub),0)))),
IF(time_PhI\PoC\PhIa>2, IF(timePhlIb>2, IF(time_PhII>2, 0,
IF(timeSub>1, (1/time_Sub),l)), IF(time_PhII>2, IF(timeSub>1,
(1/time_Sub),1), IF(time_Sub>l, 1-(1/time_Sub),0))), IF(time_PhlIb>2,
IF(time_PhII>2, IF(time_Sub>l, (1/timeSub),l), IF(time_Sub>1, 1-
(1 /timeSub),0)), IF(time_PhII>2, IF(timeSub>1, 1-(1/time_Sub),0), 0))))
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The model creates a matrix with the number of projects in each phase in each year, which
includes current and incoming groups of projects. The way that each group of projects progress
from year to year depends on the probability of success of phase transition and the time factor.
Both effects have been included in the matrix in Figure 18.
Number of Projects (including expected
time factor and success rates) timeline year
Preclinical 1 5.0 5.0 5.0 5.0 8.0 10.0 10.0 10.0 10.0 10.0 10.0
PhilPoCkPhila 2 5.0 3.8 3.8 3.8 3.8 8.0 7.5 7.5 7.5 7.5 7.5
3 0.0 5.0 3.8 3.8 3.8 3.8 6.0 7.5 7.5 7.5 7.5
iPhIlb 4 3.0 0.0 3.8 2.8 2.8 2.8 2.8 4.5 5.6 5.6 5.6
5 0.0 3.0 0.0 3.8 2.8 2.8 2.8 2.8 4.5 5.6 5.6
PhIll 6 2.0 0.0 1.3 0.0 1.6 1.2 1.2 1.2 1.2 1.9 2.4
7 0.0 2.0 0.0 1.3 0.0 1.6 1.2 1.2 1.2 1.2 1.9
Submission 8 0.0 0.0 1.2 0.0 0.8 0.0 0.9 0.7 0.7 0.7 0.7
Total Number of Projects 15.0 18.8 18.7 20.3 23.5 28.1 32.4 35.4 38.2 40.0 41.2
Figure 18: Model Calculation - Number of Projects Matrix
The at risk factor accounts for the development work that was completed on projects that fail
to transition to the following phase. Because the development work was already completed, the
headcount needs to be accounted for even though the project has failed. At risk work only applies
to Process Development, Analytical Development, Formulation, and Project Management group
activities. The at risk factor matrix is shown in Figure 19. The factor is based on the variable
percentage that is manually entered on the Input Variable tab, as described above and shown in
Figure 6.
expected
at risk Factor timeline ear
Preclinical 1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
PhKPoCPhila 2 1.06 1.06 1.06 1.06 1.06 1.06 1.06 1. 1.06 1.0 6 
3 1.086 1.06 1 1.06 1.06 1.06 1.06 1.06 1.06 1.06iPhllb 4 1.06 1.06 1.06 1.08 1.06 1.06 1.06 1.06 1.06 1.06
5 1.06 1.06 1.06 1.06 1.06 1.06 1.06 1.06 1.06 1.06
PhIll 6 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
7 1.00 1..00 1.00 1.00 1.00 1.00 1.00 1.00 to1.00 1.00
Submission 8 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Figure 19: Model Calculation - At Risk Factor
To calculate the at risk factor, the model multiplies the projects that fail by the at risk percentage
and then adds that to the projects that proceed. The following formula is an example of the at risk
factor for the first year of PhIIb development work:
=1+ (1-ratehI PhPhlIb)*at_risk_PhlIb_mAb3
The headcount per phase is taken from the appropriate headcount template matrix, as
described above and shown in Figure 1, Figure 2, and Figure 3. The user chooses between
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"Novartis data templates" or "Manual assumptions" as the source of the headcount matrix from the
drop-down menu above the upper right headcount matrix on each project type tab. The headcount
per year for each group is calculated according to the formula above and is shown in matrices by
phase and year. Each output tab has six matrices. In addition, a graph displays the totals for each
group, as shown in Figure 20.
Headcount by Group (mAb 3)
250 -
200 -
150 -
1100
50
j
2 34 5 6 7 8 910
Year
Figure 20: Model Output - Headcount by Group per Year
A Total Headcount by year matrix is obtained by summing the headcount in each group by
phase and year. The model allows for display of Total Headcount or Development Headcount,
which are calculated using the percentages from the headcount templates. A sample matrix is shown
in Figure 21.
* Process
Development
* Analytical
Development
[ Production DS
O Production DP
* Quality Control
" Formulation
* Project
Manaaement
Choose one:
Total
Total Headcount
Preclinical
PhlkPoC;Phlla
expected
timeline gear
1
2
Phllb
Submission
Total
70.0
105.0
0.0
42.0
0.0
42.0
0.0
0.0
70.0 70.0 70.0 112.0
81.6 81. 81. 81.6
108.8 81.6 81.6 81.6
0.0 55.3 41.5 41.5
65.3 0.0 81.6 61.2
0.0 26.5 0.0 33.1
42.0 0.0 26.5 0.0
0.0 3.6 0.0 2.3
259 3688 318 383 413
Figure 21: Model Output - Total Headcount by Year Matrix
140.0 140.0
130.5 183.1
81.6 130.5
41.5 41.5
61.2 61.2
24.8 24.8
33.1 24.8
0.0 2.8
140.0 140.0 140.0 140.0
163.1 163.1 163.1 163.1
163.1 163.1 163.1 163.1
66.4 83.0 83.0 83.0
61.2 97.9 122.3 122.3
24.8 24.8 39.7 49.6
24.8 24.8 24.8 39.7
2.1 2.1 2.1 2.1
513 589 848 699 738 763
The sum across the different project types is displayed on the Total Output tab. Either Total or
Development must be chosen on each of the project type tabs in order to correctly add the
headcount. This data is also portrayed as a graph, as shown in Figure 22.
Year
Total Headcount
mAb
microbial
microbial bs & v
biosimilar
Total
0 1 2 3 4 5 8 7 8 9 10
259 1010 1108 1211
126 145 88 89 64 74 73 77 78
98 109 84 77 87 72 72 78 79
175 238 189 310 389 464 477 512 545
658 1631 1775 1912
.Total Headcount
1400
1200
1000
800
600
400 -
200 -i
012345678910
Year
Figure 22: Model Output - Total Headcount by Year
E mAb
* microbial
I biosimilar
O microbial bs
The Total Output tab also displays aggregated Process Development Headcount, Analytical
Development Headcount, and Number of Projects in matrices and graphs.
1262 1297
78 78
79 79
572 583
1991 2036
YearI _
Model Output
While the output matrices and graphs give specific numbers for'headcount requirements for
each year, the Crystal Ball output forecasts show the range of headcount requirements for each year
with an associated probability distribution. The forecasts can be shown for each year, as shown in
Figure 23, or combined for multiple years, as shown in Figure 24 and Figure 25.
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Figure 23: Crystal Ball Output - Total mAb Headcount 1
330 360 390I :
SYear
O e Preferer e, Hetp
Frequency View
Figure 24: Crystal Ball Output - Total mAb Headcount Overlay Years 1 to 5
Figure 25: Crystal Ball Output - Total mAb Headcount Trend Years 1 to 5
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Another possible Crystal Ball output forecast is the range of number of projects. This can also
be shown for a specific year, as shown in Figure 26, or combined for multiple years, as shown in
Figure 27.
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Figure 26: Crystal Ball Output - Total Number of Projects by Year
___
Figure 27: Crystal Ball Output - Total Number of Projects Overlay Years 1 to 5
Scenario Analysis
To make a strategic recommendation on headcount I chose an example portfolio scenario.
This demonstrates how to think about input selection and assumption limitations as well as how to
interpret the output forecasts and translate the graphs into a strategic plan.
As inputs, the current project portfolio was translated into the model's current projects matrix,
as shown in Figure 28. In general, it is better to count projects as whole numbers in order to best
account for their resource needs in later stages. Projects that are outsourced are not included.
Outsourcing is discussed in the following section on Strategic Recommendations.
Current Projects
microbial
mAb and microbial biosimilar &
expected timeline gear phases mAb - 3 step mAb - 2 step microbial vaccine biosimilar phases mAb biosimila, Total
1 Preclinical 5 0 0 0 Start 5 10
2 Ph, PoCPhlla 5 0 1 1 2 9
3 0 0 0 1 Preclinical 0 1
4 Philb 3 0 3 1 Phi 0 7
5 0 0 0 0 Phll 3 3
S Phill 2 0 2 2 0 6
7 0 0 1 0 Submission 0 1
s Submission 0 0 0 0 0 0
15 0 7 5 10 37
Figure 28: Example Scenario - Current Projects
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For mAb and microbial incoming projects, the probability distributions account for a 60%
probability of receiving the target number of projects from Research, a 30% probability of receiving
one or two less projects (depending on the incoming number), and a 10% probability of receiving
one more project. For biosimilar incoming projects, the probability distributions account for a 50%
probability of receiving the target number of projects and a 50% probability of receiving one less
project. The timeline and probability of success distributions were left as defined. For percentage
of projects developed at risk, the realistic choice is 25% of projects. These choices are shown in
Figure 29.
Incoming Projects
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Figure 29: Example Scenario - Incoming Projects
These input choices led to the following headcount forecasts. Figure 30 displays the forecasts
for Total Headcount, Total Number of Projects, Total Process Development Headcount and Total
Analytical Development Headcount for year 1 through year 3.
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Strategic Recommendations
To translate this data into a strategic statement, I look at the headcount requirements for a
specific certainty level and then compare them across years. For example, choosing an 80%
certainty level of developing the following number of projects corresponds to requiring the
following headcount for years 2009 (year 1) to 2011 (year 3).
Year Number of Projects Total Headcount
2009 35 656
2010 44 828
2011 49 906
These forecasted numbers have an 80% probability of being needed or in other words I am
80% certain that this headcount will be required. These numbers should be used to set the
headcount for the strategic plan, differentiating between Process Development and Analytical
Development. One interesting conclusion is the rate of growth from year to year. There is a larger
jump between 2009 and 2010 than between 2010 and 2011. This is mostly due to project delays and
phase transition points. This might be a point to consider outsourcing for a portion of the growth; a
move that would increase flexibility until the higher number of projects is realized. If headcount
growth is restricted at a number below the total headcount, outsourcing contracts should be
considered to cover the expected increase in the number of projects. In this case, the model should
be rerun with a lower number of incoming projects that year to account for the ones that will be
outsourced. The difference in headcount will show the headcount saved and perhaps the monetary
worth of a third-party contract.
Summary
This is one example of the data this model contains to answer strategic planning questions.
There are several other questions that can be answered around the number of projects, facilities
required, budgets, etc. Multiple scenarios should be run and different output forecasts shown to
gain a better understanding of the model's full capabilities.
CONCLUSION
Conclusion
In summary, I would like to highlight three major findings. First, the model developed in this
work is a useful tool for forecasting not only headcount requirements across a growing biologics
portfolio, but also generally helpful for project planning where there are multiple areas of
uncertainty. Development and Operations leaders can use it to jointly determine a flexible and
responsive headcount strategy to cover the expected growth in mAb, microbial, and biosimilar
projects in the next five years. Secondly, the portfolio modeling techniques employed in this thesis
are useful to multiple groups within Biologics. Displaying the effects of time and attrition on a
prospective portfolio is essential to discussing the best strategic plan to grow an organization.
Comparing the forecasted outcomes of multiple scenarios gives managers an opportunity to define
options to mitigate potential risks with alternative strategic plans. Thirdly, workforce flexibility is an
important aspect of headcount strategy, such as transferring an idle group in Operations to an.
overworked division in Development. Outsourcing contracts with flexible numbers of projects is
another option to moderate internal growth. Overall, this model is effective in creating data to
enrich management discussions about headcount planning and other strategic decisions across the
biologics industry.
However, as this strategic planning model forecasts how projects progress, it still relies on
historical data for the timeline and probabilities of success. Since Novartis Biologics is a young
organization, the data included may not be the best predictor of future success. As discussed in The
Black Swan by Nassim Nicolas Taleb, outlier events are almost impossible to predict from historical
data. There is always a chance that all the projects will succeed or fail depending on diverse results
from the science and the clinical trial designs. There is also a chance that events external to
Development or Novartis will have a more significant impact on the projects than desired or
predicted. Users should therefore be aware that this is a finite model that will give outputs only as
reliable as the data it contains. (Taleb, 2007)
Although unpredictable clinical effects create risk and uncertainty in biologics development,
Novartis is making a sound investment in strengthening its biologics portfolio and platform. This
long-term investment should pay off with a stronger, broader portfolio. In the short-term, Novartis
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is in a great position to use its diversified portfolio to generate quarterly profits and expand its
research and development budgets.
Future Adjustments
This model can be adapted as an organizational learning tool for use in development and
production activities. Changes could be made to reflect interfaces between the two groups. I
recommend that the Development and Operations strategic planning team review the data
templates, timelines, and probabilities of success at least once per year. The model assumptions can
then be tested against actual data. The data templates were formatted to allow for straightforward
changes in number or allotment of working days per activity, new activities and percentage of work
occurring within Development. In addition, I recommend the current and projected portfolio be
reviewed quarterly to adjust the current and incoming number of projects assumptions. This could
occur in conjunction with running and analyzing a new scenario.
Further Research Considerations
In the future, it would be useful to involve finance in adapting this model to assess portfolio
cost projections. Since headcount drives internal costs, this should be straightforward. This would
allow for more data on long-range budget forecasts. I tested one prototype of the model with this in
mind and presented the results to the CFO and finance team. While they liked the idea, they
requested validation testing be performed prior to implementation.
In retrospect I would have involved the strategic planner from Operations earlier in the process
to provide feedback while formatting the model. I also would have run more scenarios with the
Development management team to provide feedback on the model capabilities and output format.
Novartis plans to continue this project and expand the model to incorporate other groups within
Development. Another idea is to explore Human Resources' view on how productivity might be
affected during a high growth phase.
BIBLIOGRAPHY
(n.d.). Retrieved January 24, 2009, from Novartis AG Web site.
DiMasi, J. A. (2007). The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and
Decision Economics, 28, 469-479.
Drews, J. (2003). Strategic trends in the drug industry. Drug Discovey Today, 8 (9), 411-420.
Heinzle, E. B. (2006). Development of Sustainable Bioprocesses: Modeling andAssessment. West Sussex: John
Wiley & Sons, Ltd.
Pisano, G. P. (2006). Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard
Business School Press.
Pisano, G. P. (1997). The Development Factory: Unlocking the Potential of Process Innovation. Boston:
Harvard Business School Press.
Rang, H. P. (2006). Drug Discovery and Development: Technology in Transistion. New York: Churchill
Livingstone.
Reichert, J. M. (2005). Monoclonal antibody successes in the clinic. Nature Biotechnology, 23 (9), 1073-
1078.
Rice, J. (1995). Mathematical Statistics and Data Anaysis (Second edition). Belmont, California: Duxbury
Press.
Stahl, J. E. (2008). Modelling Methods for Pharmacoeconomics and Health Technology Assessment.
Pharmacoeconomics, 26 (2), 131-148.
Taleb, N. N. (2007). The Black Swan: The Impact of the Highly Improbable. New York: Penguin Books.
APPENDIX A
Model File
Biologics Model v5 thesis.xls
Input
mw runt and 00cr2a2202 L2,222,.2 C 2q.1. ft]222p222' hU2R2.,22222
F4U.C21'All2BIB2".-o- tham,221222222222222222224222
*%2 3 2222.2.2w22"mw 4*vk Tia
222242222 3Sq .22 2s~ lk.222 .22.2 .222.22.2. 2$
1 2 2 2 2 1
3 211 '- 2 2 I -O 2
T 
2012
222, PP
.. 2b mkow 11 b 2n"4"
2 22 222 1221 12
Ihk W22 1472
1 20 22 2 2.
22 Wo ^M 2APWbZI k16-
2!. 722- K22 22 2
222f 7222 2 I- ZL .-- - ''; , .111 1"
I 
t
!: 
4 
fff# 
(flhj 
'-
-c'-5 
0
5
 
=
0
A
 
-
-
 
n
j%
4L 
I""~ 
~
 
~
 
ILF~TQ 
fsz" 
I 
;;z;: 
i 
"%"'
:
a
:
~
r
r
z
:] 
JIRU
M
Lf 
M
=lk5 
e
a
=
 
a 
gur::? 
tse
f-l-. 
'4:'"' 
-
n
f
-
'
-
 
-r~j;~ 
"
-
-j 
-
-
"
L
~
-
'
'
-
'
 
t
"
"
 
-
-
fl1B 
(H!H1: 
a ru 
->&
 939:: 
>
 
IRS
i~
~
 
ZiM
;-niC: 
:: 
a 
).4C 
agan 
? g
~!!!t! L~tt 
s 
a
 
w
I
o
T
~
t
-
 # 
; 
t 
:U
 
t
z
'
1 
Ir 
I 
e 
I 
I 
I 
-
I 
it
J 
)L
U U
a,:~
 
Lr:I 
~
 
"
"
"
 
' 
*
-.*
.', 
B
:C
_-:r 
t'~~:.I 
-y2-$-3 
rP
l:
nprs i 
,
.0" 
~
 
j."FI"' 
~
 
i
1 
r 
i 
A--x 
-*
:
_
 
rr 
I 
L 
~
 
~C~ 
-
rrra 
-
-
-
~
-
-
-^
---- 
-
-
~
-
-
-
~
~
~
J 
:n
: 
-
-
 
f$$##ur 
r-:
fI 
n
: 
*
:- 
jjjflaer
*
 
::±
 
::: 
$tta 
:?. 
:
It 
t 
I 
t
-
n
:. 
: 
-
' 
:0
 
:7
 
-
s
 
in
".-- 
a
 
w
a 
-
-
-
-
 
a 
:7
 
7: 
7, 
:Z:77 
a 
-
=
 
-Y
 
-
:-
' 
::M
:a
 
:T
::::; 
:
:
:
 
a
 
: 
::t::x 
-
-
-r::
-4:: 
at 
:: 
:: 
? 
tn
:::a
:a
 
a
 
?-9: :: 
: 
nl-;-:t 
a
 
::::: 
a 
:::=
2
: 
a
 
::z::t 
: 
ruT
- 
9a>
=
:::. 
:a
 
::::::.: 
-::::;-
: 
7g 
n
rag 
;re 
s: 
Is?'?? 
F 
-
~
 
a 
a
z-----ta 
2
: 
.
M
 
a
 
:a
 
0:: 
::::- 
::L
: 
:Y
::- 
U 
s2d
.
.
*
-
,
*a
 
n
u
n
 
-
9- 
.
.
,
-
.
-
.
 
ta: 
-f 
=
 
a
-**n
- 
a
 
*
 
t 
s 
as 
n 
-
aze 
a 
0:5 
' 
:::r: 
::: 
en
 
-
:::
*
 
=
:=
:: 
a 
:: 
e
s
:::::a
 
f 
*y.;- 
n
 
a
=
- 
a
 
-
=
: 
s: 
*
 
:fl: 
*
 
:-::n
-- 
-
-
,
-
.: 
-
a
::n
 
-
:t::- 
z::
5 
: 
-:::: 
u
 
-a
--- 
*
 
-
-
 
: 
: 
: ::r:- 
: 
r 
a 
-
.
-
 
-
-
-
-
-
: 
-
-
-
-
 
-
:
'I- 
'F:-: 
:-:-- 
-5 
-
-
F---:- 
Il0:-- 
ii 
-
-t-- 
-
-
-
 
' 
-
IF D: 
-
-
-
-
-
-
 
h 
-:-:-: II-:::
*
:::"=
 
i 
sal 
$e21 
i-li 
tis 
a
 
s 
ab 
a 
b 
a 
i 
b 
b 
b 
a
.
~
~JiI~ 
I 
~:i:p 
' 
I 
I 
I
-oC-4.0
0T 5* O 0
'i 
I 
ia
~ 
I::
 
I~
 
I 
iii:
i 
S
:f
Ia
t 
~
"
~
sn
sr
 
a
ii
N
* 
::
i 
N
 
N
 
*
:N
NN
 
*
N
t 
5 
( 
e
:r
::
~
~
:l
~
~
::
 =
 
?t:
tan
t; 
S-
cp
~ 
Y
L=
kf
 
::
::
:H
tl~
, 
9=
=B
 
e fut
t:U
s 
9n
r ax
 
-
=
 
=
s"
 
Ie
 
gp
:: 
:U
 
k~
fi
 
3a
 
::
n
t=
-
Ia
 
n
a
c
t:
 
*
;O
m
~ 
:u
 
g 
a
c
 
t 
s 
u 
c 
a 
2 
84
44
 
S 
a$
 
::
 
n
N
 
:0
 
0 
:q
q
 
1 
zy
 
-
-
w
a
 
S5
M
 
g
g
i 
o
 
er
rz
=
E
rf
 
r:
:=
3=
 
f:
:~
t 
*
 
a:
5~
 4
: 
,
n
Y
- 
ad
:U
 
: 
i 
r~
 
a 
::
M
 
a:
:e
En
 
~
 
a 
-
*
w
a 
2 i:r
lS;
- 
8 
Hi
gu
 
I u
su
n
cu
u N
 a
::
a 
56
$ 
::
J 
e 
3 
M
 
t 
+
a
 
N
N
; 
::
fe
 
a
 
::
ze
 
4 
l 
3 
if 
-
94
 
I
tr
 
:
 
NN
S 
N
fli
ia
N
up
 
S
 
:S
::
4
p
 
a 
ga
ny
 
: 
:?
?H
E
 
I 
*
rr
 
8 
M
Iff
 
fi
H
U
M
 
5
Bt
 
:
N
#
: 
tZ
 
Q 
;
a
N
N
"N
fiX
' 
-
*
g
fl
fi
fi
c-
fl 
I 
L 
iu
lk
 
~
 
id
~*
9 
.
l~
*"
nP
: 
'
C
-
.
 
.
; 
-
-
-
-
-
-
-
-
 
Ii
=
ss
bs
~:
a*
1
.
.
.
.
.
.
.
 
"
:"
 
U
-
-
 
-
-
 
I 
I-
_
 
L 
I 
i- 
L
II
II
 1
9 
-
1 
-
-
 
-
-
 
-
II
Output
lanai-sr
*9
T&a"ak--
f4*
445
-.a
ken
an
ttl.59u51
51*-
naa
*9*5
's.*15s4
1*29a
29*e
a
te
isrsnmutrwstskflsntnMnaanmasat:sais
'09 ~ ~ 1 U9 17w P4?
to ~ ~ ~ ~ 5 ft 60 wt5 t 2 142 t
itt ~ M YA WA' 3wit5422 4441 * ,;: V '4$ 91441 ta
15 %9 11 0 Z"* 'r 310 22A 2* 't,
iS4 21 22 20 !S Ns 2it 21 z,Fs M 29 MS 24 2i 310 WiA43 ?1 5 tit li fZ1 731 1 A i
01 4V5 5* 4 52 525
12 * 24 t, i t li ii t) 12 154 '
*5 22 29 29 22? 4* 43 415 9* Itt 114:~w: r
I4t,
1 AC 41454
it 29 "~2
I II II*i .ir i
* 44
34292
1* 16511
1S 1i 29 4 2 t ii 1 11t
5 A4A1A4 4 4 4
4 4 , , A I ,IpdO 410 it 41 t4 A9 P4 22 3 29 2 U
2 1, 4 V 4 l v9 1 30 to, *10 11t 19v
14 129 *S v46 -,I 's ?5 ai a a 4 5
% 21 s1n 2% * 21 2t NO 29 W9 1
34422 29iC~i~r*21*21 to :n15 M 0 115 4tj2 16AW 142 991 I"9 m6n $645n 15924 2
2 1 s 4 1 A 14 34.1
*T S2472 3" 4443 42 A* .4 U # 1
'q~~~~~5 tki o)M 2 21"e' 13 .
*191 5UI' 5-
APPENDIX B
User Guide
Although Crystal Ball 7.3.1 software is necessary to run the Monte Carlo simulations to arrive at
a range of forecasted headcount requirements, it is possible to gain insight into portfolio scenarios
for strategic planning just using Excel. The model file should be opened with Crystal Ball, if the
user has installed the software. Otherwise it can be opened with Excel.
The model Input Variables tab displays instructions on how to input data into the model to run
different scenarios, as shown in Figure 31. The Crystal Ball Getting Started Guide and User Manual
are valuable tools if one is not familiar with this software. They are available as pdf files under the
Start menu => Programs => Crystal Ball 7 => Documentation.
. Eir umnber ocuneutprwhjects by type a phase in yellowhiggdi tIk lt tii
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Figure 31: User Instructions
To begin, the current pipeline projects should be broken up by type (mAb, microbial, or
biosimilar) and by phase (Preclinical, Phase I\PoC\PhIIa 1" or 2nd year, Phase IIb 1"t or 2nd year,
-Phase III 1l" or 2nd year or Submission for mAb and microbial projects and Start 1"t or 2 nd year,
Preclinical, Phase I, Phase III 1" or 2nd year or Submission 1"t or 2nd year for biosimilar projects).
These numbers are entered into the top yellow-highlighted matrix.
Next, select one incoming project type and year cell (green-highlighted cells under target
heading). Then click on the Define Assumption button on the Crystal Ball toolbar or under the
Define menu. See Figure 32 for a description of the buttons on the Crystal Ball toolbar from the
Crystal Ball Getting Started Guide.
Figure A.1 The Crysal Bali toolbar
Figure 32: Crystal Ball Toolbar Descriptions
The Define Assumption window for the selected cell will open, as shown in Figure 33.
Changes to the incoming number of projects must be made in this window. To add a new number,
enter the number in the Value box and the probability in the Probability box located below the
distribution chart. Then click the Enter button for the addition to appear in the distribution chart.
To change a number that is already present, click on the green bar for the number desired to be
changed and then change the Value and/or Probability in the boxes below the distribution chart.
Again, click the Enter button for the change to appear in the distribution chart. To change the type
of probability distribution, click on the Gallery button and choose another type. When the
assumption for the selected cell has been defined, click the OK button to save the assumption and
return to the Excel spreadsheet. Repeat this for each of the incoming project types and years.
Without access to Crystal Ball, simply enter the number of projects desired to simulate in the cells
under the target column. The number shown in the cell and the Crystal Ball probability
distributions are not linked, so make sure that both agree to arrive at corresponding calculations.
Edit View Parameters P"
Name: lincom-mAb_3.yrl
Value
4.00
5.00I. .
.... .. 
Pr.b.ity Load Data...
0.6
0.1
OK Canel Eter Gallery Correlate... Help
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Similarly, to change the probability distributions for the time in phase or probability of success,
select the cell desired to be changed, open its define assumption window, and make the desired
changes as described above.
Then decide how many projects will have development activities performed at risk by project
type and phase. Enter these percentages in the appropriate yellow-highlighted cell at the bottom of
the Input Variables tab. See Figure 6 for more detail.
The final preparation step is to choose the type of headcount desired as an output, either Total
or Development. The user must choose the same type on each of the project type tabs in order for
the Total Output tab to display comprehensive numbers. In each of the project type tabs, select the
yellow-highlighted cell under Choose One: and click on the arrow to the right to display the drop-
down list. Pick one of the two choices: Total or Development. See Figure 21 for more detail.
In a similar manner, choose the source of the headcount data above the headcount matrix on
the upper right. Select the yellow-highlighted cell under Choose One: and click on the arrow to the
right to display the drop-down list. Pick one of the two choices: Novartis data templates or Manual
assumptions.
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At this point, the user will see the headcount in the matrices and on the chart on each project
type tab and the Total Output tab. These numbers reflect the outcome of the likeliest numbers
from your chosen scenario.
Finally, run the Crystal Ball simulation to display the forecast charts. Click the Start Simulation
button in the Crystal Ball toolbar. Various forecast charts will appear as the software runs the
simulation trials. Each forecast will display the headcount or number of projects range and
associated probability. Moving the arrows along the x-axis of the chart displays probabilities for
certain ranges. This is explained in more detail in the Scenario Analysis section. To see a specific
chart, such as the one shown in Figure 23, click on the Forecast Charts button in the Crystal Ball
toolbar and select the chart you wish to view. To display the outcomes on overlay or trend charts,
as shown in Figure 24 and Figure 25, click on the Overlay Charts and Trend Charts buttons.
Different assumption charts can be displayed by clicking on the Assumption Charts button.
To change the simulation parameters, click on the Run Preferences button. The user can
change the number of trials to run under this window. To reset the simulation and clear the results,
click the Reset Simulation button. To save the simulation results for future viewing, go to the Run
menu in the Control Panel and select Save Results. Choose a file name and location in which to
save the results. To restore saved results, go to the Run menu in the Crystal Ball Control Panel and
select Restore Results. Then choose the file location and name of the results for viewing.
To display additional Crystal Ball forecasts, select the desired cell within one of the output tabs
and click on the Define Forecast button in the Crystal Ball toolbar. The user will be asked to name
the cell and the units. Then click OK and rerun the simulation. To display the new output forecast,
click on the Forecast Charts button in the Crystal Ball toolbar and select the chart by its name.
